How to appeal an Elevance Health amyloidosis (cardiac attr + al) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Elevance Health-specific note: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.

What Elevance Health's policy requires for amyloidosis (cardiac attr + al)

Cited policy: BCBS Darzalex Faspro + VCd (D-VCd) for Newly-Diagnosed AL Amyloidosis

Adult with newly-diagnosed systemic AL amyloidosis confirmed by tissue biopsy + mass-spec typing OR immunoelectron microscopy identifying kappa or lambda light chains. Mayo 2012/2014 stage I-IIIa (not IIIb in many policies). Measurable hematologic disease (dFLC >=50 mg/L OR involved/uninvolved sFLC ratio abnormal OR M-protein quantifiable). Not eligible for or post ASCT. Hematologist Rx.

How Elevance Health denies amyloidosis (cardiac attr + al) — and how to counter it

Where Elevance Health pushes back: 1) Bortezomib-based induction (CyBorD) without daratumumab is sufficient first-line; 2) Reserve daratumumab for relapsed/refractory; 3) Mayo stage IIIb excluded.

Counter-arguments that hold up: ANDROMEDA (Kastritis NEJM 2021) — D-VCd vs VCd in newly-dx AL (n=388): hematologic CR 53% vs 18%, cardiac response 42% vs 22%, MRD-negativity higher with D-VCd. FDA approved Darzalex Faspro D-VCd combination on January 15, 2021 — the ONLY FDA-approved regimen specifically for AL amyloidosis. NCCN Category 1 first-line. CyBorD-without-daratumumab is now considered inferior to D-VCd for daratumumab-eligible patients. Mayo stage IIIb requires individualized review with attention to cardiac safety (slow-titration bortezomib + reduced-dose dexamethasone).

What Elevance Health typically denies for amyloidosis (cardiac attr + al)

Across Elevance Health's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:

• Step therapy
• Medical necessity for biologics
• Out-of-network for behavioral health
• Bariatric surgery prior auth

Treatments most often denied in this category

These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyndaqel / Vyndamax (tafamidis)
• Attruby (acoramidis)
• Amvuttra (vutrisiran) ATTR-CM
• Onpattro (patisiran)
• Wainua (eplontersen)
• D-VCd for AL

How to submit the appeal to Elevance Health

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Elevance Health cited in the denial.
3. File the appeal through Elevance Health's portal (members: https://www.anthem.com ; providers: https://providers.anthem.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In IN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Elevance Health's prior-authorization criteria by drug: Elevance Health PA criteria on ApprovalHelp.